Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... ... Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On ... Based in San Francisco, Doctor On Demand provides immediate access to Board Certified ...
(Date:9/1/2015)... ... 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and founder ... firm’s success in the hair care and distribution industry through her combination of ... be providing “Look and learn” live demonstrations, as well as promoting her new ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Screeners (NAPBS®) has announced that Edge Information Management has been granted ... Background Screening Credentialing Council (BSCC). , “Achieving and maintaining this accreditation ...
(Date:9/1/2015)... ... ... With former IBMers among its founding members, Inmar has known the value ... years ago. A pilot program begun by the company in 2014 has proved popular ... on pursuing careers in these fields. The program is now open to area middle ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Royal River ... new study that followed men and women for 19 years and found that, among ... did not take multivitamins. , The report is part of the September 2015 issue ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... SOA integration, and Complex-Event Processing (CEP) Technologies Unified ... 30 First Choice Professionals, LLC., today announced ... TIBX ), to provide healthcare organizations with ... solution. FCP,s renowned healthcare integration group will combine ...
... Inc. (NYSE: IMA ), a global leader in ... through the merger of rapid diagnostics and health management, announced ... C. DIFF QUIK CHEK COMPLETE (TM) rapid test as ... difficile associated disease (CDAD). This follows TECHLAB(R), Inc.,s recent ...
... Sheets: IMMB) has completed a reverse merger with a ... a 100 to 1 reverse split of stock. ... the total number of issued and outstanding shares to ... IMMB.Immunotech Laboratories, Inc. has indefinite licensing rights of the ...
... at a rate not seen in more than twenty years, creating ... insurance for small business is being called a top priority at ... and (NFIB) and America,s Health Insurance Plans (AHIP). , ... ...
... MONDAY, March 30 (HealthDay News) -- Babies who gain weight ... more prone to obesity as toddlers, Harvard researchers report. , ... much younger," said study author Dr. Elsie M. Taveras. "Even ... start guiding parents about how to prevent rapid weight gain ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today ... Annual Meeting of Stockholders. Over the past several months, ... independent directors, engaged in a rigorous process to identify ... the Board strongly believes will best serve the interests ...
Cached Medicine News:Health News:First Choice Professionals and TIBCO Announce Strategic Partnership to Advance Healthcare Integration 2Health News:Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test 2Health News:Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test 3Health News:Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test 4Health News:Immunotech Completes Merger Acquisition 2Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 2Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 3Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 4Health News:Rapid Infant Weight Gain Linked to Childhood Obesity 2Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 2Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 3Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 4
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: